fda4 min read
How FDA scientists opposed the Trump administration’s push for easier access to peptides
A plan to give Americans easier access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. was opposed by most Food and Drug Administration scientific staff members, who had limited input in drafting the policy, according to six people familiar with the policy’s development.
By Associated PressFast Company AI

Read the full story
Originally published by Fast Company AI on Oct 28, 2026.
Comments
Sign in to join the discussion.